A different class of NHE3 inhibitor, AVE-0657, has been developed by Sanofi-Aventis to treat sleep apnea (Wang et al., 2014), and related clinical trials have unfortunately abandoned. Here, SLC9A3 is linked to sleep apnea syndrome.